Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Bristol-Myers Squibb
Related studies linked through entity extraction aliases.
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
- Status
- TERMINATED
- Phase
- PHASE4
Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1